Aberdeen Group plc Has $1.20 Million Stock Position in Charles River Laboratories International, Inc. $CRL

Aberdeen Group plc boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 58.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,148 shares of the medical research company’s stock after acquiring an additional 3,021 shares during the quarter. Aberdeen Group plc’s holdings in Charles River Laboratories International were worth $1,198,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Norges Bank purchased a new stake in shares of Charles River Laboratories International in the second quarter worth approximately $76,952,000. National Bank of Canada FI increased its stake in Charles River Laboratories International by 1,179.5% in the 2nd quarter. National Bank of Canada FI now owns 434,868 shares of the medical research company’s stock valued at $65,983,000 after buying an additional 400,881 shares during the period. Balyasny Asset Management L.P. increased its stake in Charles River Laboratories International by 722.5% in the 2nd quarter. Balyasny Asset Management L.P. now owns 434,226 shares of the medical research company’s stock valued at $65,885,000 after buying an additional 381,432 shares during the period. Ariel Investments LLC lifted its position in Charles River Laboratories International by 28.6% in the 2nd quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock worth $214,751,000 after buying an additional 314,572 shares in the last quarter. Finally, LSV Asset Management boosted its stake in shares of Charles River Laboratories International by 1,773.0% during the 3rd quarter. LSV Asset Management now owns 297,800 shares of the medical research company’s stock valued at $46,594,000 after buying an additional 281,900 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 3.1%

Shares of CRL stock opened at $169.26 on Friday. The stock’s 50 day simple moving average is $200.37 and its 200 day simple moving average is $179.42. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $228.88. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.10 and a current ratio of 1.29. The company has a market capitalization of $8.33 billion, a price-to-earnings ratio of -57.18, a PEG ratio of 5.00 and a beta of 1.63.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The firm had revenue of $994.23 million during the quarter, compared to analysts’ expectations of $986.98 million. During the same quarter in the prior year, the business earned $2.66 earnings per share. The company’s revenue was down .8% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on CRL. JPMorgan Chase & Co. upped their price target on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research note on Monday, December 15th. Robert W. Baird set a $193.00 price objective on Charles River Laboratories International in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, January 21st. TD Cowen cut their price target on Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating for the company in a research note on Friday. Finally, Mizuho lowered their price target on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a research note on Friday. Ten equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $205.77.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.